The GLP-1 weight loss market is a massive one, with some analysts expecting it to be worth around $200 billion by 2031. Hype around weight loss drugs isn't new, but when people are losing more than 20% of their body weight, it creates considerable enthusiasm. And by sharing their results on social media, people are amping up that excitement to a whole new level.But to own a top drugmaker like Eli Lilly, which has an incredibly successful pair of GLP-1 drugs in Mounjaro and Zepbound, investors have to pay a ...